Diabetic nephropathy. Type 2 diabetes mellitus with diabetic nephropathy
Conditions
Interventions
Intervention 1: Intervention group: A group treated with lagglyptin 5 mg for 24 weeks. Intervention 2: Control group: A group treated with placebo for 24 weeks.
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with 6.5% to 10% glycated hemoglobin (hemoglobin HbA1c) (48 to 86 mmol / mol) Patients with BMI = 40 kg / m² The level of albumin to creatinine (UACR) ranged from 30 to 3000 mg / g creatinine (in three urine samples consecutive two weeks before the start of the study)
Exclusion criteria
Exclusion criteria: Patients who consumed rapid acting insulin, rosiglitazone, pioglitazone, GLP-1 analogues, or anti-obesity drugs three months before the start of the study Patients who had myocardial infarction, stroke, or transient ischemic attack six months before the start of the study. Patients with non-diabetic renal insufficiency or urinary tract infection Patients who have received kidney transplants
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urine Albumin-to-Creatinine Ratio. Timepoint: In three urine samples collected consecutively two weeks before the start of the study and two weeks after the start of the study and then every 4 weeks. Method of measurement: Experiments.;Blood pressure. Timepoint: At the beginning of the study, 12 and 24 weeks after the start of the intervention. Method of measurement: measurement. | — |
Secondary
| Measure | Time frame |
|---|---|
| Body mass index. Timepoint: At the beginning of the study, 12 and 24 weeks after the start of the intervention. Method of measurement: measurement.;Level glycosylated hemoglobin. Timepoint: At the beginning of the study, 12 and 24 weeks after the start of the intervention. Method of measurement: Experiments.;Glomerular filtration rate (GFR). Timepoint: At the beginning of the study, 12 and 24 weeks after the start of the intervention. Method of measurement: MDRD formula.;Liver Enzymes (ALT? AST? ALP). Timepoint: At the beginning of the study, 12 and 24 weeks after the start of the intervention. Method of measurement: Experiments.;Profile Lipid (TG? LDL? HDL? total cholesterol). Timepoint: At the beginning of the study, 12 and 24 weeks after the start of the intervention. Method of measurement: Experiments. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAshraf Aminorroaya
Esfahan University of Medical Sciences
Outcome results
None listed